SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-034892
Filing Date
2021-06-29
Accepted
2021-06-29 09:10:44
Documents
12
Period of Report
2021-06-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K tptx-8k_20210629.htm   iXBRL 8-K 48331
  Complete submission text file 0001564590-21-034892.txt   180265

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tptx-20210629.xsd EX-101.SCH 5800
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20210629_lab.xml EX-101.LAB 19675
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20210629_pre.xml EX-101.PRE 11654
5 EXTRACTED XBRL INSTANCE DOCUMENT tptx-8k_20210629_htm.xml XML 3575
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 211055912
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences